Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

ACAD

0.00

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ: ACAD) with a Market Outperform and raises the price target from $35 to $36.